The board of directors of SSY Group Limited announced that the Group has obtained the approval for drug production and registration for Nicorandil for Injection (12mg) from the National Medical Products Administration of China, being under type 3 chemical drug and regarded as passing the consistency evaluation. Nicorandil for Injection is a type of lyophilized powder for injection. It is the third approved lyophilized powder for injection products of the Group, and is mainly used for the treatment of unstable angina.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.78 HKD | +0.21% | +1.92% | -3.24% |
Apr. 23 | SSY Group Get Production, Registration Approval for Pneumonia Drug from Chinese Regulator | MT |
Apr. 16 | SSY Group Logs Nearly 15% Boost in Q1 Profit | MT |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-3.24% | 1.81B | |
+26.47% | 664B | |
+25.70% | 567B | |
-6.33% | 354B | |
+19.35% | 330B | |
+4.23% | 286B | |
+13.42% | 234B | |
+4.71% | 199B | |
-10.10% | 196B | |
-4.04% | 148B |
- Stock Market
- Equities
- 2005 Stock
- News SSY Group Limited
- SSY Group Limited Obtains Approval for Drug Production and Registration for Nicorandil for Injection from the National Medical Products Administration of China